https://ift.tt/O0Bucov from Sanofi - Aventis Groupe https://ift.tt/odI4GgF via IFTTT " May good health envelop you, spurring a q...
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
https://ift.tt/CaX3Wey from Sanofi - Aventis Groupe https://ift.tt/GFrXNxS via IFTTT " May good health envelop you, spurring a q...
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
https://ift.tt/yNkC2Ia from Sanofi - Aventis Groupe https://ift.tt/IVwDCNz via IFTTT " May good health envelop you, spurring a q...
Press Release: Availability of the Q3 2023 Memorandum for modelling purposes
https://ift.tt/9m0a7dx from Sanofi - Aventis Groupe https://ift.tt/9ZJvdn6 via IFTTT " May good health envelop you, spurring a quic...
Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
https://ift.tt/Asxqt08 from Sanofi - Aventis Groupe https://ift.tt/dBNUwZm via IFTTT " May good health envelop you, spurring a q...
Media Update: New data at ERS showed Xenpozyme® (olipudase alfa) improved respiratory functions in adults with ASMD
https://ift.tt/IGU20bz New data at ERS showed Xenpozyme ® ( olipudase alfa) improved respiratory functions in adults with ASMD f...
Media Update: New data at ERS showcases Sanofi's scientific leadership in addressing unmet needs across a variety of respiratory conditions
https://ift.tt/OoNYmTE New data at ERS showcases Sanofi's scientific leadership in addressing unmet needs across a variety of respirator...
Subscribe to:
Posts
(
Atom
)